Results 171 to 180 of about 252,165 (283)

Single‐cell analysis reveals cytotoxic and memory CD8+ T cells associated with prolonged survival in relapsed/refractory leukaemia patients after haplo+cord haematopoietic stem cell transplantation

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
1. Haplo+cord HSCT yields superior survival compared with single cord HSCT in patients with R/R leukaemia. 2. Single‐cell RNA‐seq revealed a functionally critical CD8⁺ T cell population, with cytotoxic and memory phenotypes, which expands after haplo+cord HSCT and tracks with prolonged survival. 3. Multi‐omics profiling at single‐cell resolution showed
Hua Li, Zheyang Zhang, Ming Zhu, Xiaofan Li, Jinxian Dai, Ping Chen, Fei Chen, Xianling Chen, Yiding Yang, Xiaohong Yuan, Ronghan Tang, Zhijuan Zhu, Hongli Lin, Ting Lin, Mengsha Tong, Tao Chen, Yuanzhong Chen, Jialiang Huang, Nainong Li   +18 more
wiley   +1 more source

TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]

Blood Adv
Niemann CU.
europepmc   +1 more source

CLL-IPI in MBL and CLL [PDF]

Blood, 2021
openaire   +1 more source

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice

, 2016
Heidi D. Finnes, Kari G. Chaffee, Timothy G. Call, Wei Ding, Saad S. Kenderian, Deborah A. Bowen, Michael Conte, Kristen McCullough, Julianna A. Merten, Gabriel Bartoo, Matthew D. Smith, José F. Leis, Asher Chanan‐Khan, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Tait D. Shanafelt, Sameer A. Parikh   +17 more
openalex   +2 more sources

PB2353: HEALTHCARE RESOURCE UTILIZATION AND COSTS OFF THERAPY WITH FIXED-DURATION VENETOCLAX AMONG CLL PATIENTS

, 2022
John N. Allan, Alan P Skarbnik, Nnadozie Emechebe, Hasan Alhasani, Bilal Manzoor   +4 more
openalex   +1 more source

Beyond bacterial defences: the role of lysozyme in cancer

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lysozyme (LYZ) is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment.
Lei Wang, Qian Dong, Fuchu He, Zhiwen Gu, Aihua Sun   +4 more
wiley   +1 more source

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong Christine Zhang, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Neil E. Kay   +20 more
openalex   +1 more source

Partial Nuclear Extrusion in Chronic Lymphocytic Leukemia Observed to Be an In Vitro Artefact

American Journal of Hematology, Volume 101, Issue 2, Page 337-338, February 2026.
Rima Chatila, Guillaume Beziat, Laure Pirovano, Clément Bouyssie, Jean‐Baptiste Rieu, Barbara J. Bain   +5 more
wiley   +1 more source

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Future Oncol
Shadman M, Chanan-Khan A, Campbell D, Xue M, Massoudi M, Williams R, Yang K, Tam CS.   +7 more
europepmc   +1 more source

EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia [PDF]

Magdalena Monica, Sabina Bećirović, Ioana Bianchi-Manaila, Nataša Duborija-Kovačević, Pero Draganić, Kristina Garouliene, Ariel Hammerman, Fanni Ispán, Boryana Ivanova, Agnes Männik, Gergő Merész, Lusine Nazaryan, Oleksandra Oleshchuk, Alexandra Savova, Jana Skoupá, Nikola Stefanović, Tomáš Tesař, Paweł Kawalec   +17 more
openalex   +1 more source